VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
VBIV was delisted on the 7th of August, 2024.
1 hedge funds and large institutions have $0 invested in VBI Vaccines, Inc. New Common Stock (Canada) in 2024 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 40 closing their positions.
98% less funds holding
Funds holding: 41 → 1 (-40)
100% less capital invested
Capital invested by funds: $1.79M → $0 (-$1.79M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 40
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$833K |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$402K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$122K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$118K |
| 5 |
BlackRock
New York
|
-$71.7K |
VBIV Hedge Fund Activity: Q3 2024 in Review
1 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) for Q3 2024, worth a combined $0 — down 100% from $1.79M a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of VBIV and 0 opened new positions — a net loss of 40 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Perceptive Advisors, exiting entirely with an estimated $833K sold.
- 1 institutional investor held VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) as of Q3 2024, down from 41 in Q2 2024.
- Funds reported $0 of VBI Vaccines, Inc. New Common Stock (Canada) stock for Q3 2024, down 100% quarter-over-quarter.
- 0 funds opened new VBI Vaccines, Inc. New Common Stock (Canada) positions in Q3 2024 and 40 closed out, a net change of -40 holders.
- The largest VBI Vaccines, Inc. New Common Stock (Canada) seller in Q3 2024 was Perceptive Advisors, an estimated $833K sold.
Based on aggregated 13F filings for Q3 2024.